Dossier assessment
Crizotinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Crizotinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Crizotinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Press releases
Bronchial carcinoma: added benefit of crizotinib for first-line treatment not proven
Control arm of the only study was no adequate representation of the appropriate comparator therapy
Additional information
Federal Joint Committee (G-BA)
2016-06-16 A G-BA decision was published.
Project details
- Project no.
- A15-59
- Commission
- Commission awarded on 21.12.2015 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Crizotinib (lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Crizotinib (NSCLC) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Crizotinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed